Identification of somatic mutation contributing to chemotherapy resistance in acute myeloid leukemia
| Project/Area Number |
16H06753
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Honda Akira 東京大学, 医学部附属病院, 助教 (40779394)
|
|---|
| Project Period (FY) |
2016-08-26 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 急性骨髄性白血病 / 治療抵抗性 / 遺伝子変異 / BCOR / 癌 |
|---|
| Outline of Final Research Achievements |
We aimed to reveal somatic mutations contributing to chemoresistance in primary refractory acute myeloid leukemia(AML) and to develop novel therapeutic drugs for primary refractory AML. We focused on geneX as a gene contributing to chemoresistance. Firstly, using CRISPR/Cas9 system, we generated geneX knockout human leukemic cell line. Importantly, this cell line showed chemoresistance in vitro. In addition, using xenograft mouse model, we showed that geneX knockout resulted in chemoresistance in vivo. GeneX may be highly likely to contribute to chemoresistance in AML, and we are now working on elucidating mechanisms of chemoresistance.
|
Report
(3 results)
Research Products
(3 results)
